SB-011 is under clinical development by Sterna biologicals and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SB-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SB-011 overview
SB-011 is under development for the treatment of atopic dermatitis. The drug candidate is administered through topical route. SB011 is a GATA-3-specific DNAzyme act by targeting GATA-binding factor 3 (GATA-3). It acts as an immunomodulator.
Sterna biologicals overview
sterna biologicals is a clinical-stage immunology company that develops that develops next generation antisense molecules. The company’s pipeline products include SB010, which treats asthma and chronic obstructive pulmonary disease; SB012 for ulcerative colitis and SBO11 targets Atopic Dermatitis. It develops drugs through by transcription factors in regulating underlying inflammatory mechanisms. Sterna biologicals is headquartered in Marburg, Hessen, Germany.
For a complete picture of SB-011’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
